LicianPro

Brian Chang

Equity research analyst · J.P. Morgan

Earnings calls

1

Nov 9, 2026 – Nov 9, 2026

Stocks asked about

1

Questions

3

Firm rating actions

0

on these stocks, from news

Coverage

Companies whose earnings calls Brian Chang asked questions on (from Lician's transcripts).

Questions on earnings calls

    • 55:08
      “You know, earlier, you know, you talked about how Oslo Grove has seen a lot of momentum here, specifically this month. You know, just curious if you can give us a better sense of, you know, what's driving it and how should we think about that momentum going into the new year?…”
    • 58:06
      “on my side. Maybe firstly, if you can talk about the 340B exposure from BreaMV IV and given the expected policy changes next year around 340B pricing, what could be the potential impact there on BreaMV? And secondly, on the subcute BreaMV, maybe just even qualitatively, like how…”
    • 58:41
      “Adam, maybe we want to start with the 340B exposure. Yeah, sure. So with the 340B, the policy, first of all, it's a policy that affects, you know, all buy and build drugs, not just BreaMV. It specifically impacts Medicare patients at 340B hospitals, which is a small percentage…”

Quotes are machine transcriptions of the official webcast (Whisper) and may contain errors; the timestamp opens the call at that moment.

J.P. Morgan rating actions on these stocks

From news headlines Lician stores, each linked to its source. A headline names the firm; it may not name Brian Chang. We do not use licensed rating databases.

No rating action by J.P. Morgan on these stocks in the headlines we store yet.